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Lessons Gained From Extreme-Risk Patients*Thomas Pilgrim, MD, Stephan Windecker, MDP ercutaneous coronary intervention (PCI)and transcatheter aortic valve replacement(TAVR) have started at the antipodes of the
risk spectrum. Although the former was established
in low-risk patients and later adopted in higher
risk subsets with increasing experience, TAVR was
ﬁrst introduced among inoperable patients before
extending experience to patients who were surgical
candidates. Despite the prohibitive risk proﬁle of
inoperable patients owing to comorbidities and the
procedure being in its infancy, TAVR demonstrated
a robust survival beneﬁt compared with conservative
management, and the procedural risk was offset by
the spontaneous course of the disease, underlining
the malignant course of patients with severe aortic
stenosis if untreated (1,2). Of note, it is critical to
differentiate between extreme-risk interventions on
the one hand and futile interventions on the other.SEE PAGE 1327TAVR is considered futile in patients with an esti-
mated life expectancy of <1 year and in patients in
whom comorbidities preclude the expected beneﬁt
from correction of aortic stenosis in terms of survival,
symptom relief, and quality of life. The encouraging
results in patients at highest risk subsequently pro-
pelled research to investigate the safety and efﬁcacy
of TAVR among patients at high to intermediate
surgical risk (Figure 1).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Department of Cardiology, Swiss Cardiovascular Center Bern,
Bern University Hospital, Bern, Switzerland. Dr. Pilgrim has received
speaker fees from Biotronik and Medtronic. Dr. Windecker has received
institutional research grants from Abbott Vascular, Biotronik, Boston
Scientiﬁc, Edwards Lifesciences, Medtronic, The Medicines Company,
and St. Jude Medical; and speaker fees from AstraZeneca, Abbott
Vascular, Biotronik, Biosensors, Boston Scientiﬁc, Bayer, Eli Lilly,
Edwards Lifesciences, and Medtronic.In this issue of the Journal, Yakubov et al. (3) report
the 2-year clinical outcomes after TAVR with the
self-expanding valve prosthesis (CoreValve, Med-
tronic, Minneapolis, Minnesota) among patients with
severe aortic stenosis deemed at extreme risk for
surgical aortic valve replacement (SAVR). A total
of 489 patients from 41 centers considered to
have $50% mortality or irreversible morbidity at 30
days in case of SAVR as evaluated by an interdisci-
plinary heart team underwent transfemoral TAVR.
Throughout 2 years of follow-up, rates of all-cause
mortality, cardiovascular mortality, and major
stroke were 36.5%, 26.6%, and 5.1%, respectively.
Incremental rates of adverse events between the ﬁrst
and second years of 12.3% for all-cause mortality,
7.9% for cardiovascular mortality, and 0.8% for major
stroke reﬂect the burden of comorbidities and limited
life expectancy in this elderly study population,
whereas improvement in the aortic valve effective
oriﬁce area, reduction in transvalvular gradient, and
improvement in functional class was sustained.
All-cause mortality in the present study was com-
parable to the 2-year event rates observed in
PARTNER (Placement of Aortic Transcatheter Valves)
Trial 1B (43%) and PARTNER Trial 1A (34%), and So-
ciety of Thoracic Surgeons scores >15% tended to be
predictive of 2-year mortality in the present analysis.
However, 5-year data from the PARTNER 1B study
suggested beneﬁt in favor of TAVR even in the subset
of patients with Society of Thoracic Surgeons scores
>15% compared with conservative management.
Measures of frailty as well as need for assisted living
may be clinically more meaningful and predictive
than risk scales developed for conventional SAVR to
identify patients who may no longer be candidates for
an intervention in the patient population under dis-
cussion (4,5). The ﬁndings of the extreme-risk study
with the self-expandable valve, as well as the PART-
NER 1B, suggest that conservative management
should be limited to patients with palliative
FIGURE 1 Expected Risk According to Society of Thoracic Surgeons Scores and Observed 30-Day Mortality of Patients Enrolled Into
Major TAVR Trials Over Time
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Lines represent polynomial (Poly) regression estimates for all-cause mortality (red) and Society of Thoracic Surgeons (STS) scores (blue).
PARTNER IB ¼ Placement of Aortic Transcatheter Valves (PARTNER) Trial IB; CoreValve ER ¼ CoreValve US Pivotal Trial Extreme Risk Study;
PARTNER IA ¼ Placement of Aortic Transcatheter Valves (PARTNER) Trial IA; CoreValve HR ¼ CoreValve US Pivotal Trial High Risk Study;
PARTNER II S ¼ Placement of Aortic Transcatheter Valves (PARTNER) II Sapien Trial; PARTNER II XT ¼ Placement of Aortic Transcatheter Valves
(PARTNER) II Sapien XT Trial; PARTNER II S3HR ¼ Placement of Aortic Transcatheter Valves (PARTNER) II Sapien 3 High Risk Trial; PARTNER II
S3i ¼ Placement of Aortic Transcatheter Valves (PARTNER) II Sapien 3 Intermediate Risk Trial; TAVR ¼ transcatheter aortic valve replacement.
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1336conditions, whereas additional efforts should aim to
fully exploit adequate access of extreme- and high-
risk patient populations to TAVR.
Among patients deemed inoperable, all-cause
mortality as high as 72% has been reported in the
PARTNER 1B study at 5 years and 38% in the present
study at 2 years, whereas structural valve deteriora-
tion is rare in this patient population (<3% in survi-
vors) (1,2,6,7). The discrepancy between rather low
rates of prosthesis deterioration and high rates of
clinical adverse events highlights the critical impact
of patient comorbid conditions in studies evaluating
TAVR among extreme- and high-risk populations. Of
note, survivorship bias may distort evidence of TAVR
outcomes in 2 ways. On the one hand, early death
unrelated to aortic stenosis but due to comorbidities
may limit the beneﬁts of TAVR in some patients. On
the other hand, the adverse clinical course deter-
mined by comorbidities may camouﬂage the clinical
detection of valve-related adverse outcomes, which
could emerge during longer-term follow-up. In this
context, paravalvular regurgitation amounted to
10.7% at discharge, but was unchanged between
1 and 2 years, at 4.3% and 4.4%. respectively, in
the present study. Although a paired analysis of
echocardiographic ﬁndings at discharge and 1-year
follow-up in 29 patients suggests remodeling of
the annular-bioprosthesis interface as a potential
explanation for the lower rate of paravalvularregurgitation during follow-up after self-expandable
valve implantation, attrition bias due to premature
death cannot be excluded. This is important as
moderate and severe paravalvular regurgitation has
been consistently reported as a predictor of mortality
after TAVR and constitutes the most important bar-
rier to extending the procedure to lower-risk patients
(8). Conversely, the stable transvalvular aortic valve
gradient and effective oriﬁce area throughout 2 years
of follow-up in the present study are notable. These
ﬁndings are in line with recent data of the PARTNER
1A Trial suggesting similar valve performance for
transcatheter and surgical bioprostheses through-
out 5 years of follow-up and address concerns
regarding valve durability (6). In addition, hemody-
namic measurements after TAVR suggest larger
effective aortic valve area and lower transvalvular
gradient compared with SAVR (9), hence reducing
the incidence of patient prosthesis mismatch (10).
This ﬁnding appears pronounced with use of the self-
expandable prosthesis and may be of particular
importance in patients with small valve anatomy
compared with SAVR (11).
Inevitably, the ﬁndings of the present analysis are
of somewhat historical value due to recent device it-
erations. Technical reﬁnements of newer-generation
transcatheter bioprostheses successfully minimize
the risk of paravalvular aortic regurgitation by means
of circumferential skirts at the valvular inﬂow
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1337site, mitigate the risk of vascular access site and
bleeding complications due to lower proﬁle delivery
catheters, and reduce the risk of atrioventricular
conductance disturbances related to more precise
positioning within the annulus. Outcomes based on
recent iterations of balloon-expandable and reposi-
tional transcatheter valve systems have reported
signiﬁcant improvements, with rates of paravalvular
aortic regurgitation mimicking results of SAVR and
very low rates of periprocedural mortality (12,13)
(Figure 1).
Presence of coronary artery disease was predictive
of all-cause mortality at 2 years in the present ana-
lysis. Available observational data on the impact of
coronary artery disease on clinical outcomes among
patients undergoing TAVR are equivocal and limited
by the small sample size, relatively short duration
of follow-up, substantial heterogeneity in terms of
anatomic and physiological extent of coronary artery
disease, and selection bias introduced by revascular-
ization (14). Of note, patients with previous PCI/
coronary artery bypass grafting and those in need for
revascularization were excluded from participation in
the present study. Notwithstanding, more advanced
coronary artery disease (SYNTAX score >22) and
extent of ischemia may be associated with adverse
clinical outcome after correction of aortic stenosis
and requires careful consideration in therapeutic
decision making (14,15).
The risk of thromboembolic cerebrovascular acci-
dents is greatest within the ﬁrst hours after TAVR
and is a function of patient age, severity of aortic
valve stenosis, extent of aortic arch atheroma, post–
valve deployment balloon dilation, and repeated
prosthesis placement (16). The optimal type and
duration of antithrombotic and antiplatelet treat-
ment after TAVR remain to be deﬁned as well as the
role of dedicated cerebral protection devices (17,18).
In the present study, the risk of stroke was 8.6% at
2 years and rather stable between 1 and 2 years of
follow-up. Moreover, recent data from the CoreValve
US Pivotal Trial High Risk Study demonstrate a trend
toward a lower risk of stroke after TAVR compared
with SAVR (11).
Atrioventricular conductance disturbances with
the need for permanent pacemaker (PPM) implan-
tation occur more frequently with self-expandablecompared with balloon-expandable prostheses. In
the present study, the rate of PPM implantation
was 22% at 30 days, 26% at 1 year, and 29% at
2 years. The most important predictors of PPM
implantation include intraoperative atrioventricular
block, right bundle branch block, implantation of a
self-expandable TAVR prosthesis, left anterior
hemiblock, ﬁrst-degree atrioventricular block, and
male sex (19). However, PPM implantation has not
been associated with adverse clinical outcome after
TAVR so far, and device iterations aiming at more
precise positioning of the prosthesis within the
annulus may further mitigate the frequency of this
adverse event (20).
In summary, TAVR in extreme-risk patients not
only improves survival but has pronounced effects on
quality of life, symptom and functional status as well
as cognitive function. With a number needed to treat
of <5 to prevent 1 death among inoperable patients,
TAVR has resulted in a paradigm shift in the treat-
ment of patients with severe aortic stenosis. In line
with recent guidelines on valvular heart disease in
Europe and the United States, TAVR has become the
standard of care in inoperable patients (Class IB) and
a valuable alternative to SAVR among high-risk pa-
tients (Class IIaB) (21,22). Challenges to be addressed
in the future will be to improve education and timely
access to medical care as well as adequate reim-
bursement. Although evidence from randomized
clinical trials suggests similar or superior outcomes of
TAVR compared with SAVR among high- and
intermediate-risk patients with severe aortic stenosis
(6,9,11), the ongoing reﬁnement of the procedure and
TAVR prostheses will catalyze research among lower-
risk patients. The expansion of TAVR to lower-risk
patients further raises the bar in terms of outcomes
and shifts the focus beyond patient-related to
prosthesis-related outcomes. Although TAVR has
started at the extreme end of the risk spectrum, it has
the potential to mature into a procedure for all pa-
tients with severe aortic stenosis, irrespective of risk,
in the future.
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